Paper - WANFANG MED ONLINE

You Position: Home > Paper

Mucormycosis occurred during tigecycline treatment for infections caused by extensively resistant gram negative bacilli infection: report of two cases

( views:0, downloads:0 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 6

DOI:: 10.3760/cma.j.issn.1674-2397.2020.06.010

Key Word:: 毛霉病;革兰氏阴性杆菌;替加环素;恶性肿瘤;Mucormycosis;Gram negative bacillus;Tigecycline;Malignant tumor

Abstract：毛霉病是一种常见于血液系统恶性肿瘤、糖尿病酮症酸中毒、中性粒细胞减少、皮质类固醇治疗、铁超载、严重创伤、烧伤和器官移植受者中的感染性疾病。尽管目前临床上针对毛霉病有多个治疗选择，但其病死率仍然较高。早期诊断对于该病的治疗具有重要意义。本文报道2例血液系统恶性肿瘤患者在使用替加环素治疗广泛耐药革兰阴性杆菌感染时，取得良好疗效，但继发毛霉感染，最终导致预后不佳的病例。

Reference

[1]Corzo-Leon, Dora E.,Chora-Hernandez, Luis D.,Rodriguez-Zulueta, Ana P.,etc.Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases[J].2018,56(1).
[2]P.E. Verweij,G.M. González,N.P. Wiederhold,etc.In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries[J].2009,21(3).
[3]Kwon-Chung,K.J..Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives[J].2012,54(Suppl.1).
[4]George, Petrikkos,Anna, Skiada,Olivier, Lortholary,etc.Epidemiology and clinical manifestations of mucormycosis.[J].2012,54 Suppl 1.
[5]E. Bouza,P. Muñoz,J. Guinea.Mucormycosis: an emerging disease?[J].2006,12.
[6]Tissot, Frederic,Agrawal, Samir,Pagano, Livio,etc.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J].2017,102(3).
[7]Vanover Sams-CL,Ribes JA,Baker DJ.Zygomycetes in human disease.[J].2000,13(2).
[8]Kontoyiannis DP,Lionakis MS,Lewis RE,etc.Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.[J].2005,191(8).
[9]V. Rickerts,Angelika Böhme,Gudrun Just‐Nübling.Risikofaktoren für invasive Zygomykosen bei Patienten mit hämatologischen Neoplasien[J].2002,45(S1).
[10]Oren, Ilana.Breakthrough Zygomycosis during Empirical Voriconazole Therapy in Febrile Patients with Neutropenia.[J].2005,40(5).
[11]Bala, Kiran,Punia, Rajpal Singh,Attri, Ashok Kumar,etc.A prospective study of mucormycosis in north India: Experience from a tertiary care hospital[J].2015,53(3).
[12]G. N. Pongas,R. E. Lewis,G. Samonis,etc.Voriconazole‐associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?[J].2009,15.
[13]Arendrup, Maiken Cavling,Jensen, Rasmus Hare,Meletiadis, Joseph.In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order[J].2015,59(12).
[14]Edwards J Jr,Ibrahim A,Spellberg B.Novel perspectives on mucormycosis: pathophysiology, presentation, and management.[J].2005,18(3).
[15]Roden, Maureen M.,Zaoutis, Theoklis E.,Buchanan, Wendy L.,etc.Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases.[J].2005,41(5).
[16]Francisco M, Marty,Lisa A, Cosimi,Lindsey R, Baden.Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.[J].2004,350(9).